Kardigan completes enrollment in two late-stage cardiovascular trials, reports Q3 2026 resultsNov 12Quarterly updateataciguatdanicamtiv
Kardigan registers Phase 3 open-label extension for danicamtiv in genetic DCMAug 18Trial updatedanicamtivKardigan
Kardigan advances three late-stage cardiovascular trials, reports $660.7M cashAug 11Quarterly updatedanicamtivKardigan